Home > Healthcare > Pharmaceuticals > Vaccines > mRNA Vaccine Market

mRNA Vaccine Market Trends

Report ID: GMI6076
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

mRNA Vaccine Market Trends

The rising awareness and demand for vaccination coupled with the efficacy and potential of mRNA vaccines will significantly drive the market share. Growing awareness regarding vaccination for preventing infectious diseases and avoid epidemics and pandemics has led to a significant surge in mRNA-based vaccines. Also, mRNA vaccines offer high efficacy rates and have proven its potential to stimulate robust immune responses, providing enhanced protection against targeted pathogens. Further, rising government initiative and R&D activities to develop novel vaccines for various genetic disorders, autoimmune disease and various types of cancer is anticipated to fuel the industry outlook.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

mRNA vaccine industry size was worth USD 11.3 billion in 2022 and is projected to expand at 9.6% CAGR to reach USD 27.7 billion by the end of 2032 driven by the high prevalence of infectious diseases and genetic disorders worldwide.

Demand for self-amplifying mRNA vaccines reached 50.9% of the market share in 2022 and is estimated to grow at a notable CAGR from 2023-2032 attributed to their increasing adoption to achieve dose-sparing effects.

North America held more than 42.4% share of the mRNA vaccine market in 2022 and is anticipated to exhibit considerable growth through 2032 attributed to the presence of well-established healthcare infrastructure and the increasing R&D investments by led key market players.

Some of the mRNA vaccine firms include AstraZeneca, Pfizer Inc., Moderna, Inc., and GlaxoSmithKline among others.